Search All UT System Experts

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study

M. L. Rothenberg, J. V. Cox, C. Butts, M. Navarro, Y. J. Bang, R. Goel, S. Gollins, L. L. Siu, S. Laguerre, D. Cunningham

Research output: Contribution to journal › Article › peer-review

178 Scopus citations

Fingerprint

Dive into the research topics of 'Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study'. Together they form a unique fingerprint.

Medicine & Life Sciences